COMPANY

IN8bio

HQ: New York, NY source · in8bio.com ↗ · Southeast

The Company is developing allogeneic, autologous, iPSC and genetically modified gamma-delta T cell therapies. From company website Source · Oct 12, 2026

Keywords: cell therapies

Profile checked Oct 10, 2026

$40.2MRaised (2 yrs)

Timeline

Dec 19, 2025 Raise Private placement: $40.2M (up to, as announced), announced Dec 19, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Dec 30, 2025 SEC Form D ↗

Funding

Raised: $40.2M. Last 2 years.

Dec 19, 2025 Private placement: $40.2M (up to, as announced), announced Dec 19, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Dec 30, 2025 SEC Form D ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-12-30 Raise Private raise (SEC Form D): $20.1M sold of $40.2M offered; issuer “IN8BIO, INC.”. Verified from the SEC filing. SEC filing ↗
2024-10-15 Raise Private raise (SEC Form D): $12.4M sold; issuer “IN8BIO, INC.”. Verified from the SEC filing. SEC filing ↗